Chugai Pharmaceutical Co., Ltd. is a research‑based Japanese pharmaceutical company and a majority‑owned member of the Roche Group. Headquartered in Tokyo, it discovers, develops, manufactures, and markets prescription medicines with core strengths in oncology, immunology/inflammation, hematology, and rare diseases. The company is known for its expertise in biologics and antibody engineering.
Chugai’s portfolio includes innovative monoclonal antibodies and small molecules, with notable therapies such as Actemra (tocilizumab), Hemlibra (emicizumab), Alecensa (alectinib), and Enspryng (satralizumab). It collaborates closely with Roche and Genentech on global development and commercialization, and distributes Roche medicines in Japan. Chugai operates R&D and manufacturing facilities primarily in Japan and participates in international clinical programs, supplying biologics to global markets.
